Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: A meta-analysis of randomized double-blind controlled trials

Yiqing Song, K. He, E. B. Levitan, J. E. Manson, S. Liu

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Aims: The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes. Methods: We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA1c) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI). Results: After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA 1c between magnesium supplementation groups and control groups was not significant [-0.31% (95% CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride. Conclusions: Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.

Original languageEnglish (US)
Pages (from-to)1050-1056
Number of pages7
JournalDiabetic Medicine
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Magnesium
Type 2 Diabetes Mellitus
Meta-Analysis
Confidence Intervals
Fasting
Blood Pressure
HDL Cholesterol
Glucose
Glycosylated Hemoglobin A
LDL Cholesterol
Blood Glucose
Body Mass Index
Therapeutics
Cholesterol
Placebos
Databases
Lipids
Safety
Control Groups

Keywords

  • Controlled trials
  • Glycaemic control
  • HbA levels
  • Magnesium supplementation
  • Meta-analysis

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes : A meta-analysis of randomized double-blind controlled trials. / Song, Yiqing; He, K.; Levitan, E. B.; Manson, J. E.; Liu, S.

In: Diabetic Medicine, Vol. 23, No. 10, 01.10.2006, p. 1050-1056.

Research output: Contribution to journalArticle

@article{dadc67d4c93e4450bf8df825c3469df7,
title = "Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: A meta-analysis of randomized double-blind controlled trials",
abstract = "Aims: The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes. Methods: We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA1c) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95{\%} confidence interval (CI). Results: After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95{\%} CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA 1c between magnesium supplementation groups and control groups was not significant [-0.31{\%} (95{\%} CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95{\%} CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride. Conclusions: Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.",
keywords = "Controlled trials, Glycaemic control, HbA levels, Magnesium supplementation, Meta-analysis",
author = "Yiqing Song and K. He and Levitan, {E. B.} and Manson, {J. E.} and S. Liu",
year = "2006",
month = "10",
day = "1",
doi = "10.1111/j.1464-5491.2006.01852.x",
language = "English (US)",
volume = "23",
pages = "1050--1056",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes

T2 - A meta-analysis of randomized double-blind controlled trials

AU - Song, Yiqing

AU - He, K.

AU - Levitan, E. B.

AU - Manson, J. E.

AU - Liu, S.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Aims: The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes. Methods: We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA1c) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI). Results: After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA 1c between magnesium supplementation groups and control groups was not significant [-0.31% (95% CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride. Conclusions: Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.

AB - Aims: The aim of this study was to assess the evidence on the effect of oral magnesium supplementation on glycaemic control in patients with Type 2 diabetes. Methods: We searched the electronic databases of medline, embase and the Cochrane Controlled Trials Register up to January 2005. We identified nine randomized double-blind controlled trials with a total of 370 patients with Type 2 diabetes and of duration 4-16 weeks. The median dose of oral magnesium supplementation was 15 mmol/day (360 mg/day) in the treatment groups. The primary outcome was glycaemic control, as measured by glycated haemoglobin (HbA1c) or fasting blood glucose levels; the secondary outcomes included body mass index, blood pressure (BP) and lipids. Using a random-effects model, we calculated the weighted mean differences (WMD) and 95% confidence interval (CI). Results: After a median duration of 12 weeks, the weighted mean post-intervention fasting glucose was significantly lower in the treatment groups compared with the placebo groups [-0.56 mmol/l (95% CI, -1.10 to -0.01); P for heterogeneity = 0.02]. The difference in post-intervention HbA 1c between magnesium supplementation groups and control groups was not significant [-0.31% (95% CI, -0.81 to 0.19); P for heterogeneity = 0.10]. Neither systolic nor diastolic BP was significantly changed. Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride. Conclusions: Oral magnesium supplementation for 4-16 weeks may be effective in reducing plasma fasting glucose levels and raising HDL cholesterol in patients with Type 2 diabetes, although the long-term benefits and safety of magnesium treatment on glycaemic control remain to be determined.

KW - Controlled trials

KW - Glycaemic control

KW - HbA levels

KW - Magnesium supplementation

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=33748757640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748757640&partnerID=8YFLogxK

U2 - 10.1111/j.1464-5491.2006.01852.x

DO - 10.1111/j.1464-5491.2006.01852.x

M3 - Article

C2 - 16978367

AN - SCOPUS:33748757640

VL - 23

SP - 1050

EP - 1056

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 10

ER -